{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:42:41Z","timestamp":1791650561272,"version":"4.3.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a case of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis following enfortumab infusions that was ultimately fatal. The second case describes an erythema multiforme-like rash with interface dermatitis related to enfortumab. Dermatologic findings, immunohistochemistry studies, and immune profiling are detailed. These cases demonstrate the potentially catastrophic outcomes in some patients treated with enfortumab. Patients must be monitored for cutaneous toxicities with early involvement of dermatology and dermatopathology.<\/jats:p>","DOI":"10.3389\/fonc.2021.621591","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T08:51:04Z","timestamp":1614847864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":55,"title":["Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction"],"prefix":"10.3389","volume":"11","author":[{"given":"Paul V.","family":"Viscuse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario L.","family":"Marques-Piubelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan M.","family":"Heberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin Roger","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doina","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B2","unstructured":"Seattle Genetics and Astellas Announce PADCEV\u00ae (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer [news release]Bothell, Washington and Tokyo"},{"key":"B3","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3252042890","article-title":"Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma","volume":"25","author":"Wu","year":"2019","journal-title":"Dermatol Online J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma","author":"Chang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218791314","article-title":"Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy","volume":"25","author":"Hwang","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.08.008","article-title":"Increased frequencies of Th17 cells in drug eruptions","volume":"73","author":"Fujiyama","year":"2014","journal-title":"J Dermatol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.08.042","article-title":"Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"131","author":"Teraki","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.129.1.92","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jtos.2015.10.002","article-title":"Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis\u2013A Comprehensive Review and Guide to Therapy. I. Systemic Disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul Surf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001527","article-title":"Pembrolizumab-Induced Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report","volume":"42","author":"Robinson","year":"2020","journal-title":"Am J Dermatopathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflam, Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e12832","DOI":"10.1111\/dth.12832","article-title":"Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature","volume":"32","author":"Wang","year":"2019","journal-title":"Dermatol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0167120","DOI":"10.1371\/journal.pone.0167120","article-title":"The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis","volume":"11","author":"Ye","year":"2016","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.839","article-title":"Recurrence and Mortality Following Severe Cutaneous Adverse Reactions","volume":"311","author":"Finkelstein","year":"2014","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.621591\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:11:03Z","timestamp":1671495063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.621591\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":25,"alternative-id":["10.3389\/fonc.2021.621591"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.621591","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"article-number":"621591"}}